Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lymphoma drug combo trial halted early – what we know

NCT ID NCT03769181

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were collected, the full potential of this approach remains unclear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
isatuximab and cemiplimab
What this could lead to
If successful, this combination could offer a new treatment option for people with certain types of lymphoma that have not responded to other therapies.
What could go wrong
The trial was terminated early, so results are limited. It is still early-stage research, and the combination may not prove effective or safe for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma diffuse large B-cell lymphoma lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

  • Investigational Site Number :1580002

    Taichung, 40447, Taiwan

  • Investigational Site Number :2500001

    Villejuif, 94800, France

  • Investigational Site Number :2500002

    Nantes, 44093, France

  • Investigational Site Number :2500004

    Montpellier, 34295, France

  • Investigational Site Number :2500005

    Dijon, 21000, France

  • Investigational Site Number :2500007

    Pessac, 33600, France

  • Investigational Site Number :3800002

    Bologna, 40138, Italy

  • Investigational Site Number :3800003

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number :3800006

    Brescia, 25123, Italy

  • Investigational Site Number :4100001

    Gangnam-gu, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number :4100002

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number :5280001

    Maastricht, 6229 HX, Netherlands

  • Investigational Site Number :5280002

    Amsterdam, 1081 HV, Netherlands

  • Investigational Site Number :6200002

    Coimbra, 3000-075, Portugal

  • Investigational Site Number :6200003

    Porto, 4200, Portugal

  • Investigational Site Number :6200004

    Lisbon, 1649-035, Portugal

  • Investigational Site Number :7240002

    L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain

  • Investigational Site Number :7240003

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number :7240004

    Madrid / Madrid, Madrid, Comunidad de, 28040, Spain

  • Investigational Site Number :7240005

    Barcelona, Barcelona [Barcelona], 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.